ArticleCurrent oncology (Toronto, Ont.)2021

Response to Combination of Pembrolizumab and Axitinib in Hereditary Leyomiomatosis and Renal Cell Cancer (HLRCC).

Ibon Gurruchaga Sotés et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.